What is Tacrolimus and How to Prescribe It
Tacrolimus (Protopic®) is a topical calcineurin inhibitor that you should prescribe as 0.1% ointment applied twice daily to the affected areas of the ears and neck for this pruritic, desquamating rash, particularly if this represents atopic dermatitis or therapy-resistant eczematous dermatitis. 1, 2
What Tacrolimus Is
Tacrolimus is a macrolide immunosuppressant that works by inhibiting calcineurin, which blocks the synthesis of proinflammatory cytokines and downregulates T-cell activity. 3, 4 It is available as an ointment in two strengths:
- 0.03% for children aged 2-15 years
- 0.1% for adults and children ≥16 years 2
The medication has minimal systemic absorption through intact skin and does not cause skin atrophy, unlike topical corticosteroids. 3, 4
How to Prescribe Tacrolimus for Ear and Neck Dermatitis
Prescription Details
- Strength: Tacrolimus 0.1% ointment (for adults/adolescents ≥16 years) 2
- Frequency: Apply twice daily to affected areas 2
- Amount: Thin layer only—use the smallest amount needed to control symptoms 2
- Duration: Short-term or intermittent long-term treatment; stop when symptoms resolve 5, 2
Specific Application Instructions for Patients
- Wash hands before application 2
- Apply thin layer to pruritic, desquamating areas on ears and neck 2
- Do not bathe, shower, or swim immediately after application to avoid washing off the ointment 2
- Wash hands after application (unless treating the hands) 2
- Can apply moisturizers after tacrolimus, not before 2
Evidence for Ear and Neck Use
For chronic external otitis and ear dermatitis specifically, tacrolimus 0.1% has demonstrated 85% improvement rates with significant reduction in pruritus, erythema, edema, and desquamation. 6, 7 In these studies, an ear wick containing 0.1% tacrolimus was changed every 2-3 days for three applications total, with 46% achieving complete remission over 10-22 months. 6
The face and neck are preferred sites for topical calcineurin inhibitors because these areas are more susceptible to corticosteroid side effects like skin atrophy. 8
FDA-Approved Indications and Guidelines
Tacrolimus is FDA-approved for short-term or intermittent long-term treatment of atopic dermatitis in patients ≥2 years who are unresponsive to or intolerant of conventional therapies. 5, 2 The 2023 American Academy of Dermatology guidelines provide a strong recommendation with high certainty evidence for tacrolimus 0.1% and 0.03% ointments in treating atopic dermatitis. 1
Critical Safety Considerations and Contraindications
Black Box Warning
The FDA requires a black box warning regarding theoretical cancer risk, though long-term safety studies show the absolute risk of lymphoma is low and not clinically meaningful. 1, 5 Despite this:
- Do not use continuously for prolonged periods 2
- Only apply to areas with active eczema 2
- Never use in children <2 years old 2
Absolute Contraindications
- Children younger than 2 years 2
- Compromised immune system 5
- Netherton's syndrome (impaired skin barrier leading to systemic absorption) 5, 2
- Active skin infections (bacterial, viral including herpes/chickenpox) 2
Sun Protection Requirements
- Limit sun exposure during treatment 2
- Wear loose-fitting protective clothing over treated areas 2
- Do not use UV light therapy, sun lamps, or tanning beds concurrently 2
When to Reassess
Call for follow-up if: 2
- Symptoms worsen with treatment
- Skin infection develops
- No improvement after 6 weeks of treatment (may indicate alternative diagnosis)
Common Pitfalls to Avoid
- Do not cover with occlusive dressings or bandages—normal clothing is acceptable 2
- Avoid eyes and mouth; do not swallow 2
- Most common side effect is transient burning/stinging at application site, which typically resolves early in treatment 6, 7, 4
- If using moisturizers, apply them after tacrolimus, not before 2
Sample Prescription
Rx: Tacrolimus 0.1% ointment
Disp: 30 grams
Sig: Apply thin layer to affected areas on ears and neck twice daily. Wash hands before and after application. Avoid sun exposure to treated areas. Discontinue when rash resolves or after 6 weeks if no improvement.